China-based Haixi Pharmaceuticals has submitted a Hong Kong Stock Exchange (HKEX) listing application, showcasing a portfolio of 14 approved generics including mosapride and amlodipine + atorvastatin, plus four innovative candidates. The company reported 2025 first-five-month revenue of RMB 249 million (USD 35 million; +67% year-on-year), driven by national bulk procurement wins capturing 25% to 59% market share in key categories. Its lead asset C019199, a first-in-class CSF-1R/DDR1/VEGFR2 inhibitor for osteosarcoma, is set to enter Phase III trials this year.

Haixi's pipeline includes oral wet age-related macular degeneration (wet AMD) therapy HXP056 entering Phase I, and glioma drug HXP089 targeting 2026 IND submission. The company operates 36 global patents and supplies over 18,000 Chinese hospitals. Proceeds will fund R&D expansion and overseas commercialisation of innovative assets.

According to PharmCube's MedAlpha® database, in 2022 Haixi received a USD 14 million strategic investment from Zhongtian Fortune and Hongshi Capital. Click here to request a free trial for MedAlpha®.